Pulse Biosciences, Inc. (PLSE)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$53.07-6.99%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · PLSE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-04.
The screen ranks PLSE against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools.
Stated in 2 of 2 supplied quarters. Management reported: “Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools.” “ex_1021860.htm Exhibit 99.1 Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse ™ Cardiac Catheter System for Atrial Fibrillation Treatment 164 evaluable patients enrolled across 15 clinical sites HAYWARD, California, October 7, 2026, Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites.”
“Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools.”
“● Commenced enrollment in NANOPULSE-AF, the U.S. IDE pivotal clinical trial, with first patients treated in early April 2026.”
|| ● | Generated $434 thousand of second quarter revenue, representing sequential growth over the first quarter.
Stated in 2 of 2 supplied quarters. Management reported: “|| ● | Generated $434 thousand of second quarter revenue, representing sequential growth over the first quarter.” “Soft Tissue Ablation ● Generated $0.4 million in revenue from nPulse Vybrance capital and disposables.”
“|| ● | Generated $434 thousand of second quarter revenue, representing sequential growth over the first quarter.”
Cash and cash equivalents totaled $101.6 million as of June 30, 2026, compared to $106.3 million as of June 30, 2025 and $68.3 million as of March 31, 2026.
Stated in 2 of 2 supplied quarters. Management reported: “Cash and cash equivalents totaled $101.6 million as of June 30, 2026, compared to $106.3 million as of June 30, 2025 and $68.3 million as of March 31, 2026.” “Cash used in operating activities in the second quarter of 2026 totaled $18.7 million, compared to $12.8 million used in the same period in the prior year, and $14.6 million used in the first quarter of 2026.”
We are pleased to project trial completion across three sites in under one year.
Stated in 2 of 2 supplied quarters. Management reported: “We are pleased to project trial completion across three sites in under one year.” “● Completed enrollment of first 50 patients in PRECISE-Benign Thyroid Nodule study, and expanded potential enrollment to 100 patients.”
“We are pleased to project trial completion across three sites in under one year.”
Add key leadership roles to support clinical trial execution and commercial preparation.
Over the trailing year it converted 0.78x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“Soft Tissue Ablation ● Generated $0.4 million in revenue from nPulse Vybrance capital and disposables.”
“Cash and cash equivalents totaled $101.6 million as of June 30, 2026, compared to $106.3 million as of June 30, 2025 and $68.3 million as of March 31, 2026.”
“Cash and cash equivalents totaled $68.3 million as of March 31, 2026, compared to $119.3 million as of March 31, 2025 and $80.7 million as of December 31, 2025.”
“● Completed enrollment of first 50 patients in PRECISE-Benign Thyroid Nodule study, and expanded potential enrollment to 100 patients.”